When GSK’s new CEO Luke Miels told investors last month that “smart business development” is a key pillar for his strategy, he wasn’t lying. | Like Merck & Co.’s PAH drug Winrevair—which brought in $1 ...
GSK is continuing to bolster its siRNA portfolio by paying $40 million upfront for a pair of oligonucleotide therapies from ...
Investor's Business Daily on MSN
This rare disease biotech name teases around a buy point
This company develops treatments for rare genetic diseases. It partners with Biogen.
Perched on the cliffs of Torrey Pines, investors, CEOs, and scientists this week debated whether U.S. biotechs are losing ground to China. Meanwhile, across the Pacific, Chinese companies were busy ...
Makary pointed to three bottlenecks: hospital contracting; ethical reviews and approvals; and the Investigational New Drug ...
As Demy-Colton and EBD Group’s Biotech Showcase™ concluded its 18th year SAN FRANCISCO, CA, UNITED STATES, February 10, ...
AI is rewriting biotech’s commercial playbook—cutting waste, shrinking teams, and giving first‑time drugmakers a faster, smarter path to launch.
Journey Medical dermatology revenue plus Emrosi near-term sales and a rare pediatric disease PRV from Zycubo approval. See ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Grail (GRAL) stock is plummeting after the company's three-year cancer screening trial failed to meet its main goal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results